Detection of Myocarditis With Microbubbles and normal coronary arteries. Because phosphatidyl serinecoated microbubbles have already been shown to be safe in clinical trials, 10 additional studies should now be performed to determine its efficacy in detecting these common clinical problems with molecular echo imaging techniques.
T here are several commercially available microbubbles throughout the world. Although their primary indications are for either improving left ventricular opacification or enhancing liver imaging, these agents have also been used clinically for off-label applications, such as myocardial and tumor perfusion imaging. 1, 2 The reason such practices are permissible is that these applications provide critical additional clinically useful information with the same doses of microbubbles required for the approved indication, and the imaging techniques required to perform these off-label applications are available on almost all commercially available scanners. To get Food and Drug Administration approval for any new indication or modification of the microbubble in the United States, additional expensive clinical trials and safety data (in the case of microbubble shell modifications) would be required. This becomes especially problematic for targeted molecular imaging applications with microbubbles, where specific ligands must be attached to microbubbles in order for them to be retained at sites where receptor upregulation occurs in various disease states like reperfusion injury, 3 localized myocardial inflammation after ischemia, 4 
See Article by Steinl et al
In the setting of myocarditis, clinical studies and expert review papers have recommended magnetic resonance imaging as the modality of choice. 6, 7 However, the diagnostic accuracies of most magnetic resonance imaging protocols that rely on a combination of T2-weighted edema detection with black blood imaging, hyperemic perfusion with T1-weighted imaging, and delayed enhancement imaging to detect myocarditis are <80%. Steinl et al created a murine model of varying severities of autoimmune myocarditis and, at 21 days, intravenously injected microbubbles that were targeted to either CD4 on lymphocytes or endothelial P-selectin. 5 Subsequent molecular imaging of retained targeted microbubble contrast was effective at detecting the presence of myocarditis. Traditional echocardiographic measurements like ejection fraction and left ventricular mass were not effective in distinguishing normal myocardium from active myocarditis. Contrastenhanced molecular imaging detected both moderate and severe forms of myocarditis with targeted microbubbles, whereas other advanced forms of ultrasound imaging (longitudinal strain) were only able to identify severe forms of myocarditis. 3 Although the CD4 and P-selectin targeted microbubbles clearly could improve diagnostic accuracy, it would require conjugation of anti-P-selectin or anti-CD4 antibodies to the microbubble surface. For such a targeted microbubble to be used in clinical practice, extensive safety testing would be required first. However, the authors of this study used a third targeted microbubble that consisted of simply adding a negatively charged phospholipid to the fluorocarbon microbubble. Specifically, this was done by sonication of decafluorobutane gas with an aqueous dispersion of 1 mg/ mL polyethylene glycol stearate, 2 mg/mL distearoyl phosphatidylcholine, and 0.3 mg/mL of the negatively charged phospholipid distearoyl phosphatidylserine. Although the CD4 targeted microbubbles were useful in identifying the pathogenesis of myocarditis in this setting, the incorporation of a negatively charged phospholipid like phosphatidyl serine into the bubble membrane was just as effective at myocarditis detection with molecular imaging as were the ligand-targeted microbubbles. Phosphatidyl serine within the microbubble shell seems to enhance complementmediated opsonization and subsequent attachment to both leukocytes and inflamed microvascular endothelium. 8 This same complement-mediated inflammation is also seen within the myocardial risk area after even brief periods of ischemia, and, therefore, phosphatidyl serine microbubbles have been used with molecular imaging approaches to detect ischemia reperfusion injury 4 and, more recently, brief periods of remote ischemia 8 (Table) . These findings have significant clinical implications because phosphatidyl serine containing microbubbles are already commercially available in certain countries for liver imaging in Japan and South Korea. 9 Therefore, similar to perfusion imaging, molecular imaging may be possible with currently approved microbubbles. These off-label uses would provide critical information in areas where clinicians still lack accurate bedside imaging techniques that could aid in rapid decision making, such as detection of remote ischemia in patients with a recent episode of chest pain, rapidly defining risk area in acute coronary syndromes, and as was shown in the current study, detection of myocarditis in patients presenting with acute chest pain
